diabetes and more
Follow
Find
41.9K views | +36 today
diabetes and more
Important news for those concerned with all types of diabetes, associated autoimmune diseases, & health
Your new post is loading...
Your new post is loading...
Scooped by Ellen H Ullman, MSW
Scoop.it!

American Diabetes Association Applauds the Passage of LouisianaSenate Bill 759

American Diabetes Association Applauds the Passage of LouisianaSenate Bill 759 | diabetes and more | Scoop.it

American Diabetes Association Applauds the Passage of Louisiana Senate Bill 759
Bill Will Ensure Children With Diabetes Are Safe at School

ALEXANDRIA, VA, Jun 18, 2012 (MARKETWIRE via COMTEX) -- The American Diabetes Association is pleased to announce the passage of Louisiana Senate Bill 759, a key piece of legislation in the fight to keep children with diabetes safe at school. This bill, which was signed by Governor Bobby Jindal on Friday, allows school employees to volunteer to be trained to help children with diabetes with essential care tasks. These tasks include administering insulin, which is needed multiple times a day, and glucagon, a hormone needed in the case of dangerously low blood glucose levels. This bill also allows children, if they are capable to do so, to self-manage their diabetes while at schoo

more...
No comment yet.
Scooped by Ellen H Ullman, MSW
Scoop.it!

OHIOH: Scholarship fund to help diabetic children

OHIOH: Scholarship fund to help diabetic children | diabetes and more | Scoop.it
NEWARK -- The Central Ohio Diabetes Association has renewed the William W. Cooksey Camp Hamwi Memorial Scholarship Fund for children with diabetes in Licking County. The fund was established by family and friends to honor his memory.
more...
No comment yet.
Scooped by Ellen H Ullman, MSW
Scoop.it!

F.D.A. Investigates Dialysis Company Fresenius for Failure to Warn of Risk

F.D.A. Investigates Dialysis Company Fresenius for Failure to Warn of Risk | diabetes and more | Scoop.it
The company, Fresenius Medical Care, may have failed to tell customers that one of its products was connected to a potentially lethal risk.
more...
No comment yet.
Scooped by Ellen H Ullman, MSW
Scoop.it!

Diachieve Donates 50,000 Glucose Tablets to Diabetes Camp for Kids

Pompano Beach, FL (PRWEB) June 15, 2012 Diachieve has donated 50,000 glucose tabs to Camp Ho Mita Koda, a summer camp located near Cleveland, Ohio whose mission is to enable children to live well with diabetes through an enjoyable camp experience.
more...
No comment yet.
Scooped by Ellen H Ullman, MSW
Scoop.it!

Dexcom Receives CE Mark Approval for the Dexcom G4® Continuous Glucose Monitoring System | Business Wire

Dexcom Receives CE Mark Approval for the Dexcom G4® Continuous Glucose Monitoring System | Business Wire | diabetes and more | Scoop.it
Dexcom Receives CE Mark Approval for the Dexcom G4® Continuous Glucose Monitoring System...
more...
No comment yet.
Scooped by Ellen H Ullman, MSW
Scoop.it!

Governor Gregoire and Congressman McDermott Join Novo Nordisk at Opening Event for Type 1 Diabetes Research Center in Seattle

Governor Gregoire and Congressman McDermott Join Novo Nordisk at Opening Event for Type 1 Diabetes Research Center in Seattle | diabetes and more | Scoop.it

Governor Gregoire and Congressman McDermott Join Novo Nordisk at Opening Event for Type 1 Diabetes Research Center in Seattle

SEATTLE, June 13, 2012 /PRNewswire via COMTEX/ -- Novo Nordisk NVO -0.21% hosted a community event today to celebrate the official opening of Novo Nordisk's new type 1 Diabetes R&D Center in Seattle, which will explore innovative approaches to treat and prevent type 1 diabetes.

more...
No comment yet.
Scooped by Ellen H Ullman, MSW
Scoop.it!

Researchers find new cause of cardiac damage after heart attack in type 1 diabetes | Science Codex

Researchers find new cause of cardiac damage after heart attack in type 1 diabetes | Science Codex | diabetes and more | Scoop.it
Boston – June 13, 2012 -- After people with type 1 diabetes have a heart attack, their long-term chance of suffering even more heart damage skyrockets. But the reason has long puzzled scientists.
more...
No comment yet.
Scooped by Ellen H Ullman, MSW
Scoop.it!

Type 1 diabetes on the rise among young people in the U.S.

Jeffrey Brewer, president and CEO of JDRF, the leading global organization focused on type 1 diabetes (T1D) research, issued the following statement today in response to a new study showing an increase in T1D among young people in the United States.
more...
No comment yet.
Scooped by Ellen H Ullman, MSW
Scoop.it!

data developed in rat and mouse models cannot always be translated into human outcomes.

data developed in rat and mouse models cannot always be translated into human outcomes. | diabetes and more | Scoop.it

The Company’s Metabolism PhysioLab® Platform demonstrates why data developed in rat and mouse models cannot always be translated into human outcomes.

more...
No comment yet.
Scooped by Ellen H Ullman, MSW
Scoop.it!

Mindfulness-Based Diabetes Management (MBDM)

Mindfulness-Based Diabetes Management (MBDM) | diabetes and more | Scoop.it

Mindfulness-Based Diabetes Management (MBDM) is a stress management course designed to meet the unique self-care demands and challenges of living with either Type 1 or Type 2 diabetes. Research shows that ongoing stress management is essential to achieve optimal treatment outcomes and maintain quality of life for people living with diabetes. Based on the latest research on stress, the mind/body connection, self-compassion, diabetes burnout, and motivating and sustaining healthy behaviors, the MBDM course teaches concrete skills and techniques for managing stress to live well with diabetes.

more...
No comment yet.
Scooped by Ellen H Ullman, MSW
Scoop.it!

Ampio Pharma climbs on data for eye drug Optina - BusinessWeek

THE BIG PICTURE: The Greenwood Village, Colo., company said the results come from a small trial involving 32 patients. It plans to meet with the Food and Drug Administration in July to discuss further testing of Optina.

The drug is intended to treat diabetic macular edema, or swelling of the macula of the eye. It is a common cause of blurred vision and blindness. Ampio said almost all type 1 diabetes patients and most type 2 diabetes patients eventually develop the condition, but there is no drug to treat it -- although conditions that control diabetes symptoms are effective.

more...
No comment yet.
Scooped by Ellen H Ullman, MSW
Scoop.it!

Positive Results from First Human Clinical Trials of a First-Generation Artificial Pancreas System is Significant Step Forward for Millions with Type 1 Diabetes

WEST CHESTER, Pa., June 11, 2012 /PRNewswire/ -- Results from the first feasibility study of an advanced first-generation artificial pancreas system were presented today at the 72nd Annual American Diabetes Association Meeting in Philadelphia. ...
more...
No comment yet.
Scooped by Ellen H Ullman, MSW
Scoop.it!

Echo Therapeutics Presents Positive Clinical Trial Results of the Symphony® tCGM System

PHILADELPHIA, June 12, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, presented an expanded analysis of data collected from subjects with either type 1 or type 2 diabetes during its recent clinical trial of its Symphony tCGM System. The data were presented during an oral presentation session on Friday, June 8 at the 72nd Annual Scientific Sessions of the American Diabetes Association (ADA) in Philadelphia, PA..

more...
No comment yet.
Scooped by Ellen H Ullman, MSW
Scoop.it!

Israeli Medicine Breakthrough - For the First Time in the World and at the Initiative and Under the Leadership of Schneider Children's Specialists: The Artificial Pancreas MD-Logic was Tested in a ...

Digital Journal is a digital media news network with thousands of Digital Journalists in 200 countries around the world. Join us!
more...
No comment yet.
Scooped by Ellen H Ullman, MSW
Scoop.it!

DexCom Proudly Sponsors Historic Diabetes Flight Formation Trip toRaise Juvenile Diabetes Research Foundation Funds

DexCom Proudly Sponsors Historic Diabetes Flight Formation Trip to Raise Juvenile Diabetes Research Foundation Funds
Cross-Country Flight to Inspire People With Diabetes That Sky's the Limit When It Comes to Fulfilling One's Dreams

SAN DIEGO, CA, Jun 15, 2012 (MARKETWIRE via COMTEX) -- DexCom DXCM +2.26% , the leader in continuous glucose monitoring, is proudly sponsoring the efforts of the Diabetes Formation Flight USA (DFFUSA.org) -- three pilots with insulin-dependent diabetes using DexCom's Seven Plus as part of their effort to set new transcontinental world speed records while raising funds for the Juvenile Diabetes Research Foundation (JDRF).

The historic dusk-to-dawn flight will take place sometime between June 25 and July 3, 2012, depending on weather conditions. The flight begins in Daytona Beach, Fla., and ends in San Diego, Calif., 13 to 15 hours later. This flight will be particularly demanding due to the duration and challenge of maintaining the two-aircraft formation.

DFF USA aims to show that modern technology for diabetes management, including Continuous Glucose Monitoring (CGM), combined with a strict management regimen can enable people with insulin-dependent diabetes to effectively handle their condition while performing even the most challenging tasks -- such as flying cross-country while setting world records.

more...
No comment yet.
Scooped by Ellen H Ullman, MSW
Scoop.it!

From “Dada” to “Father of the Bride” Jeff Hitchcock founder@cwdiabetes via @DiabetesMine J

From “Dada” to “Father of the Bride” Jeff Hitchcock founder@cwdiabetes via @DiabetesMine J | diabetes and more | Scoop.it

In honor of Father’s Day (which is this Sunday, in case you forgot), we’re honored to bring a few words from the man himself on what it means to be a father of a CWD. Even when she’s a married lady…

more...
No comment yet.
Scooped by Ellen H Ullman, MSW
Scoop.it!

Orgenesis' Sarah Ferber, Ph.D on Using a Diabetes Patient's Own Liver Cells as a Novel Source of Insulin

Orgenesis' Sarah Ferber, Ph.D on Using a Diabetes Patient's Own Liver Cells as a Novel Source of Insulin | diabetes and more | Scoop.it
Diabetes currently afflicts approximately 285 million people worldwide, about 6.4 percent of the global population.
more...
No comment yet.
Scooped by Ellen H Ullman, MSW
Scoop.it!

Gene Map of Body's Microbes Is Health Tool

Gene Map of Body's Microbes Is Health Tool | diabetes and more | Scoop.it
Researchers said Wednesday they have produced the first comprehensive genetic map of the microbes that live in or on a healthy human body, laying the groundwork for possible new advances in research and in the diagnosis and treatment of disease.
more...
No comment yet.
Scooped by Ellen H Ullman, MSW
Scoop.it!

Spring Travels: Around the World with Celiac Experts and Dietitians

Spring Travels: Around the World with Celiac Experts and Dietitians | diabetes and more | Scoop.it
In my last post, I described where the first half of my spring travels took me – Orlando, Manhattan and Washington, DC. Now, I’m going to fill you in on an international trip and other domestic...
more...
No comment yet.
Scooped by Ellen H Ullman, MSW
Scoop.it!

JDRF and Novo Nordisk Establish R&D Collaboration for Type 1 #diabetes

JDRF and Novo Nordisk Establish R&D Collaboration for Type 1 #diabetes | diabetes and more | Scoop.it

JDRF and Novo Nordisk Establish R&D Collaboration for Type 1 Diabetes
-- Focus Will Be on Disease-Modifying Immunotherapies for Type 1 Diabetes--

Contact:
William Sorensen
wsorensen@jdrf.org
(212) 479-7558

New York, NY and Copenhagen, Denmark, June 13, 2012-To address the underlying autoimmune process that is central to type 1 diabetes (T1D), JDRF and Novo Nordisk are partnering to discover and develop novel immunotherapies to prevent, treat, and help cure the disease. Type 1 diabetes occurs when the body's immune system attacks and destroys the glucose-responsive, insulin-secreting beta cells of the pancreas, resulting in a lifetime requirement of insulin replacement therapy.

The collaboration between JDRF and Novo Nordisk will focus on research originating from academia and biotechnology companies, as well as from internal research projects at Novo Nordisk.

"JDRF is deeply committed to developing immunotherapies, and especially auto antigen-specific immunotherapies for the prevention and cure of type 1 diabetes," said Dr. Richard Insel, JDRF's chief scientific officer. "This collaboration with Novo Nordisk affords an exciting opportunity to accelerate the timeframe when these therapies may prove to make an impact in type 1 diabetes."

The collaboration with Novo Nordisk will be run out of the company's newly opened Type 1 Diabetes Research and Development (R&D) Center in Seattle. The center, led by Dr. Matthias von Herrath, plans to employ 20 immunotherapy researchers working in Seattle supported by corporate R&D functions in Princeton, NJ and Denmark. The center's goal is to use translational research methods to rapidly move early-stage discovery projects in immunotherapy from animal models into small clinical exploratory trials in T1D.

"It is not a coincidence that we are opening our new Type 1 Diabetes Research and Development Center in Seattle at that same time that we announce a scientific partnership between our company and JDRF," said Mads Krogsgaard Thomsen, executive vice president and chief science officer at Novo Nordisk. "Our new R&D center is founded on the principle of reaching out to academia, biotechnology companies, and other key players in the international immunotherapy research community in order to join forces to develop the next treatment advance in the management of type 1 diabetes. At Novo Nordisk, our vision is to prevent, treat, and ultimately cure diabetes, and every collaboration down that path brings us closer to that goal."

more...
No comment yet.
Scooped by Ellen H Ullman, MSW
Scoop.it!

(MICE) Experimental Drug May Protect From Type 1 Diabetes

(MICE) Experimental Drug May Protect From Type 1 Diabetes | diabetes and more | Scoop.it
JDRF-funded researchers have found that an experimental drug, called TUDCA, can dramatically reduce the occurrence of type 1 diabetes...
more...
No comment yet.
Scooped by Ellen H Ullman, MSW
Scoop.it!

Liquid glucagon formulation may be useable in standard diabetes pumps

JDRF-funded researchers at Oregon Health & Science University (OHSU) and Legacy Health have discovered a liquid glucagon formulation that may be useable in standard diabetes pumps. Such a formulation could broaden the use of glucagon to help prevent hypoglycemia in people with type 1 diabetes (T1D) who are treated with insulin. It could also open a path to future-generation artificial pancreas systems that dispense more than just insulin for optimizing glucose control.

"Our previous studies have shown that the injections of small amounts of glucagon prevent hypoglycemia, which is a frequent and serious complication of type 1 diabetes that can lead to seizures, loss of consciousness, and even death," said W. Kenneth Ward, M.D., associate professor of medicine (endocrinology, diabetes, and clinical nutrition) at OHSU School of Medicine and senior scientist at Legacy Health, the two Portland, OR-based organizations that collaborated on the study. The research was presented at the American Diabetes Association's (ADA) 72nd Scientific Sessions on Friday, June 8, and on Sunday, June 10, in Philadelphia.

more...
No comment yet.
Scooped by Ellen H Ullman, MSW
Scoop.it!

glu - a community for people with type one #diabetes

glu is a way for people with type 1 diabetes to stick together. To find each other, learn from each other, and help each other.
more...
No comment yet.
Scooped by Ellen H Ullman, MSW
Scoop.it!

Youth use poetry to raise #diabetes awareness

Youth use poetry to raise #diabetes awareness | diabetes and more | Scoop.it
San Francisco youth have armed themselves with poetry in the fight against diabetes.
more...
No comment yet.
Scooped by Ellen H Ullman, MSW
Scoop.it!

Lilly's Investigational Basal Insulin Shows Better Results than Lantus

Lilly's Investigational Basal Insulin Shows Better Results than Lantus | diabetes and more | Scoop.it
Eli Lilly investigational novel basal insulin analog was associated with greater improvements of glycemic control than Lantus in patients with type 1 diabetes.
more...
No comment yet.